DS-1123
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Malignant Tumors
Conditions
Advanced Solid Malignant Tumors
Trial Timeline
Jan 1, 2016 → Nov 1, 2017
NCT ID
NCT02690337About DS-1123
DS-1123 is a phase 1 stage product being developed by Daiichi Sankyo for Advanced Solid Malignant Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT02690337. Target conditions include Advanced Solid Malignant Tumors.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02690337 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Solid Malignant Tumors